The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas. [electronic resource]
Producer: 20170629Description: 1859-69 p. digitalISSN:- 1538-8514
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Caspase 3 -- metabolism
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Disease Models, Animal
- Drug Resistance, Neoplasm
- Drug Synergism
- Humans
- Hydrazones -- pharmacology
- Indoles -- pharmacology
- Melanoma -- drug therapy
- Mice
- Mutation
- Phosphorylation
- Piperazines -- pharmacology
- Proto-Oncogene Proteins B-raf -- genetics
- Sulfonamides -- pharmacology
- Tumor Burden -- drug effects
- Vemurafenib
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.